Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).

Rana R McKay Bradley Alexander McGregor Wanling Xie David A BraunXiao WeiChristos E KyriakopoulosYousef ZakhariaBenjamin L MaughanTracy L RoseWalter M Stadler David F McDermott Lauren C HarshmanToni K Choueiri

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

In this study, nivolumab followed by two doses of ipilimumab resulted in no CRs and a low PR/CR conversion. The number of patients evaluated for nivolumab discontinuation was too small to assess the value of this approach. Currently, our data do not support a response-adaptive strategy for checkpoint blockade in advanced RCC.

Keyphrases

phase ii study
renal cell carcinoma
end stage renal disease
newly diagnosed
chronic kidney disease
dna damage
open label
prognostic factors
clinical trial
squamous cell carcinoma
locally advanced
cell cycle
randomized controlled trial
cell proliferation
rectal cancer